Sleep State in Lung Cancer: A Retrospective Analysis

NCT06953492 | Completed

• 1 other identifier: SD-lung cancer-Retrospective
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer remains the leading cause of cancer-related mortality globally, with tumor progression closely linked to the immune microenvironment. Sleep disorders (e.g., insomnia, obstructive sleep apnea \[OSA\]) affect 40-50% of lung cancer patients and may promote tumorigenesis via chronic inflammation, immune suppression, and metabolic dysregulation. Preclinical and epidemiological studies suggest that chronic sleep deprivation reduces NK cell activity, elevates pro-inflammatory cytokines (IL-6, TNF-α), and upregulates angiogenic factors (VEGF), though clinical evidence remains scarce. This study aims to: Evaluate associations between sleep disorders and immunosuppressive phenotypes (e.g., PD-L1 expression, T-cell exhaustion) in lung cancer patients. Analyze the impact of sleep disturbances on immunotherapy efficacy (e.g., PD-1 inhibitors) and prognostic outcomes. Explore underlying mechanisms, including hypoxia-inducible factor (HIF-1α) signaling and sympathetic nervous system activation

Conditions

Lung Adenocarcinoma; Sleep Disorders, Circadian Rhythm

Outcome Measures

Primary Outcomes (1)

• OS

  Overall survival (OS) : time from immunotherapy initiation to all-cause death

  Baseline

Study Arms (1)

Lung cancer

lung cancer-Non SD; lung cancer-SD

Other: PSQI

Interventions

PSQI OTHER

PSQI

Lung cancer

Eligibility Criteria

• Age: 20 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

1\. Data source and time range Data source: Adult patients (≥18 years old) diagnosed with primary lung cancer (confirmed by histopathology) in \[Zhong Shan Hospital\] from January 2018 to January 2025 were retrospectively enrolled. Data extraction: Clinical, pathological and follow-up data were collected through the electronic medical record system (EMR) and the hospital cancer registry database.

You may qualify if:

• NSCLC or SCLC was diagnosed.
• Patients have received immunotherapy (e.g., PD-1/PD-L1 inhibitors) or standard treatment (chemotherapy/radiotherapy).
• Sleep disorder diagnoses and immune-related biomarkers fully recorded in medical records.

You may not qualify if:

• The patient had a history of other malignant tumors.
• Key clinical data lacking.
• The presence of a serious psychiatric or neurologic condition.

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Sites (1)

Zhong Shan hospital

Shanghai, China

Location

MeSH Terms

Conditions

Adenocarcinoma of Lung; Sleep Disorders, Circadian Rhythm

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Chronobiology Disorders; Nervous System Diseases; Dyssomnias; Sleep Wake Disorders; Occupational Diseases; Mental Disorders

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2025
• First Posted: May 1, 2025
• Study Start: January 1, 2018
• Primary Completion: January 1, 2025
• Study Completion: January 1, 2025
• Last Updated: May 1, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)